Bridge Therapeutics is dedicated to helping physicians and patients by developing better therapies for Opioid Use Disorder (OUD) and moderate to severe chronic pain.

BT-219 is a superior formulation of buprenorphine-naloxone compared to competing therapies so it should aid compliance with Medication Assisted Treatment (MAT) for OUD.  BT-205 should provide a safe alternative to the too often addictive, ineffective, and dangerous opioids that are currently on the market for chronic pain, e.g., morphine, oxycodone, hydromorphone and fentanyl.

Please fill out the form below to contact us and learn more about how our drug candidates can aid Medication Assisted Treatment of OUD and provide better pain management with less risk of addiction or overdose compared to current therapies for chronic pain.